Myostatin (GDF-8) is the primary negative regulator of skeletal muscle mass. Loss-of-function mutations produce the "double muscling" phenotype in cattle (Belgian Blue), dogs (whippets), and humans (Schuelke 2004). Pharmacological inhibition is the obvious therapeutic goal for sarcopenia, cachexia, and - the current launch narrative - the 15–40% lean mass loss caused by GLP-1 receptor agonists (semaglutide, tirzepatide).
The follistatin binding loop (3HH2:C/D, res 41–54) is the starting point for the DF-series peptide lineage on this platform. Takayama et al. (2020, 2021) showed that short peptides derived from this loop can inhibit myostatin in vitro.
GDF-8, or myostatin, is the primary brake on skeletal muscle mass in vertebrates - and the most validated target for muscle-building peptide research. It signals through ACVR2B to suppress satellite cell proliferation and drive atrophy via Smad2/3. Loss-of-function mutations produce the "double-muscled" phenotype in Belgian Blue cattle, bully whippets, and at least one documented human case with roughly 2× muscle mass from birth. Every scaffold designed to increase lean mass without androgens eventually points here.
Myostatin is synthesized as a 375-aa precursor, cleaved by furin at an RSRR site to release a ~110-aa mature homodimer stabilized by a cystine-knot motif. The prodomain holds the dimer in a latent complex until BMP-1/tolloid metalloproteinases disrupt it. Active dimer binds ACVR2B with sub-nM affinity, recruits ALK4/5/7, and phosphorylates Smad2/3 → Smad4 nuclear translocation → suppression of MyoD targets and mTOR/Akt signaling. Activin A and GDF-11 use the same receptor; blocking myostatin alone produces substantial hypertrophy, but pan-ACVR2B blockade produces more. Natural antagonists - follistatin, GASP-1, and the propeptide itself - define the endogenous buffering system that peptide scaffolds can mimic or displace.
No myostatin inhibitor is approved for human use as of 2026. Apitegromab (Scholar Rock) is in late-stage trials for spinal muscular atrophy; GYM329 (Roche) targets SMA and GLP-1-associated muscle loss; taldefgrobep alfa (Biohaven) is in obesity trials. All are antibody-based and WADA-prohibited. The field's failures - stamulumab, domagrozumab - increased muscle mass on DXA but failed functional endpoints, which is the design lesson for any card forked from this target. Follistatin gene therapy (AAV1-FST344) showed functional gains in Becker MD Phase 1/2a, making follistatin-mimetic peptides an active recipe space. Resistance training alone cuts myostatin mRNA ~20–50% and raises follistatin, confirming the axis is pharmacologically accessible.
VNDNTLFKWMIFNG · 14 aa · @peptidemodel
| # | id | title | author | status | refs | ipSAE_d0chn | ♥ |
|---|---|---|---|---|---|---|---|
| 1 | pep-00127 | Muscle-growth booster peptide (DF-3) | pe@peptidemodel | 8 | 0.742 | 0 | |
| 2 | pep-10791 | Muscle-growth booster peptide: follistatin fragment (1-27) | pe@peptidemodel | 1 | — | 0 | |
| 3 | pep-10785 | Muscle-growth booster peptide (myostatin prodomain minimum peptide 1) | pe@peptidemodel | 5 | — | 0 |
No discussion threads yet.